tiprankstipranks
H.C. Wainwright reiterates Buy on ImmunoGen following MIRASOL ‘homerun’
The Fly

H.C. Wainwright reiterates Buy on ImmunoGen following MIRASOL ‘homerun’

H.C. Wainwright analyst Swayampakula Ramakanth notes that Immunogen reported strong top-line results from the Phase 3 MIRASOL study in patients with folate receptor alpha-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy. The firm believes the "robust" data set from MIRASOL paves a smooth path to a full approval for Elahere. H.C. Wainwright believes Elahere’s superiority to chemotherapy demonstrated in MIRASOL further reinforces the therapeutic potential of the drug in patients with FRalpha-positive ovarian cancer. Given that, it expects Elahere to be increasingly used in off-label patient populations, such as platinum-sensitive as well as earlier lines of ovarian cancer patients with FRalpha expression. H.C. Wainwright reiterates a Buy rating on the shares with a price target of $15.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on IMGN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles